TM4SF5 DIAGNOSIS METHOD OF LIVER DISEASES AND SCREENING METHOD OF TREATMENT AGENT FOR LIVER DISEASES USING TM4SF5 PROTEIN EXPRESSION LEVEL CHANGE

摘要

The present invention relates to a method for diagnosing obesity, liver disease, and a screening method for treating liver disease using TM4SF5 protein expression changes. Specifically, the present invention is metabolic disorder occurs in the transgenic mouse overexpressing TM4SF5 protein, Srebp1, Srebp2, Fasn, CD36, Fabp1, Vldlr, Ldlr, ApoB100, Pparα, Pparγ, Leptin, Accα, Accß or SREBP1c mRNA or protein Increased expression, increased levels of monoacyl-, diacyl-, and triacyl-glycerol, STAT3, c-Src, or FAK Protein phosphorylation is reduced to show the characteristics of fatty liver and hepatitis, and if the transgenic mice are continuously raised, SREBP1, SREBP2, Fasn, CD36, Fabp1, Vldlr, Ldlr, ApoB100, Pparα, Pparγ, Leptin, Accα, Accß, or SREBP1c Reduced protein expression, increased phosphorylation of STAT3, c-Src, or FAK protein, increased synthesis of extracellular matrix including laminin γ2, laminin, and collagen, showing characteristics of liver fibrosis or cirrhosis, and sick mice When overexpressing TM4SF5 in kind Diagnosis of obesity and liver disease by measuring the expression change of TM4SF5 protein by confirming an increase in expression of proteins of liver cancer markers including cotton CD34, AFP, FUCA (AFU), Cyclin D1, Ki67, or HIF1-α, or , It can be useful for screening candidates for the prevention or treatment of obesity and liver disease.